| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733877 | Current Problems in Cancer | 2017 | 9 Pages |
Abstract
Both anti-PD1 and anti-PDL1 therapies can lead to psoriasis exacerbation although more severe flares were noted in patients treated with durvalumab. Not only personal but also related family history of psoriasis are significant risk factors and need to be outlined before treatment initiation. If such related history exists, strict skin surveillance can lead to the early diagnosis and treatment of any psoriatic exacerbations that could otherwise severely affect quality of life or even compromise therapeutic protocols and final prognosis.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Dimitra MD, Vasiliki. MD, Konstantinos MD, Andriani MD, Nikolaos MD, Ioanna MD, Ioanna MD, Gerasimos MD, K. MD, A. MD,